DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.

Migraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and will have to report any migraine attacks they have during the study's 18-week follow up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents

NCT00195741

Migraine

COMPLETED PHASE3

MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

NCT00797667

Migraine

TERMINATED PHASE2

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

NCT03885154

Migraine in Children

TERMINATED PHASE2

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

NCT00195754

Migraines

COMPLETED PHASE3

Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine

NCT00195806

Migraine

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The multi-center trial has a double-blind, randomized, placebo-controlled, parallel-group design and will be carried out in Israel. Approximately 40 adult subjects with migraine will be randomly assigned (1:1) to either DP-VPA (maximum of 900mg/day) or placebo. Active and placebo will be administered orally and once-daily on an add-on basis, i.e. other permissible ongoing medications will be continued. Total study duration per subject will be 18 weeks. Subjects will report on their migraine attacks frequency and other attack characteristics using weekly diaries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

DP-VPA

Group Type EXPERIMENTAL

DP-VPA

Intervention Type DRUG

DP-VPA dose escalation to 900mg, then continued for 8 weeks

B

Group Type PLACEBO_COMPARATOR

DP-VPA Placebo

Intervention Type DRUG

Matching Placebo to Active, dose escalation, then continued for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DP-VPA

DP-VPA dose escalation to 900mg, then continued for 8 weeks

Intervention Type DRUG

DP-VPA Placebo

Matching Placebo to Active, dose escalation, then continued for 8 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects with migraine with or without aura fulfilling the diagnostic criteria of the International Classification of Headache Disorders
* 3 to 6 migraine attacks per month
* Concomitant prophylactic migraine treatment with a beta-blocker or amitriptyline that has been stable in the proceeding 3 months. No changes in this concomitant treatment will be allowed until the end of study follow-up.

Exclusion Criteria

* Migraine complicated by medication-overuse headache.
* Allergy or hypersensitivity to valproic acid, valproate sodium, or soy.
* Known contraindications to valproic acid.
* Pregnancy.
* Breastfeeding female subjects.
* Subjects with significant hepatic dysfunction indicated by SGOT or SGPT \>3 times the upper limit of normal at screening.
* Renal impairment indicated by serum creatinine \>1.5mg/dL at screening.
* Potentially fertile and sexually active women who do not practice reliable contraception.
* Men who do not practice reliable barrier contraception.
* Concomitant use of antipsychotic, antidepressant or antiepileptic therapy - with the exception of amitriptyline - within 1 month of screening, or a medical condition that is likely to require such treatment during the trial participation.
* An active central nervous system disease deemed to be unstable or progressive during the course of the study that may confound the interpretation of the study results.
* Any medical disorder that may makes the subject unlikely to fully complete the study- Blood coagulation disorder.
* Concomitant drugs known to interact with VPA.- Alcohol or other drugs abuse.
* Therapy with another investigational product within 30 days prior start of study.
* Concomitant participation in another trial or study

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No